Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Cash & Equivalents (2024 - 2025)

Evommune (EVMN) has disclosed Cash & Equivalents for 2 consecutive years, with $44.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 171.07% to $44.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.1 million, a 171.07% increase, with the full-year FY2025 number at $44.1 million, up 171.07% from a year prior.
  • Cash & Equivalents was $44.1 million for Q4 2025 at Evommune, up from $26.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $44.1 million in Q4 2025 to a low of $16.3 million in Q4 2024.